Statements (58)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biotechnology company
|
| gptkbp:acquisition |
gptkb:CureVac_AG
|
| gptkbp:CEO |
gptkb:Sandy_Macrae
|
| gptkbp:clinicalTrials |
Phase 1
personalized medicine public company Phase 2 Phase 3 hemophilia sickle cell disease beta-thalassemia cell-based therapies gene-based therapies |
| gptkbp:collaborations |
academic institutions
biopharmaceutical companies gene therapy advancements genome editing innovations |
| gptkbp:community_engagement |
patient advocacy groups
scientific community healthcare_professionals |
| gptkbp:employees |
approximately 200
|
| gptkbp:financialPerformance |
volatile
|
| gptkbp:focus |
gene therapy
genome editing cell therapy |
| gptkbp:focus_area |
cancer
genetic disorders rare diseases |
| gptkbp:founded |
1995
|
| gptkbp:founder |
gptkb:Edward_Lanphier
|
| gptkbp:future_plans |
increase partnerships
enhance technology platform expand pipeline |
| gptkbp:headquarters |
gptkb:Richmond,_California
|
| https://www.w3.org/2000/01/rdf-schema#label |
Sangamo Therapeutics
|
| gptkbp:investmentFocus |
institutional investors
Venture capital firms |
| gptkbp:market |
approximately $500 million (2021)
|
| gptkbp:partnerships |
gptkb:Pfizer
Sanofi |
| gptkbp:patentCitation |
therapeutic applications
gene editing technologies |
| gptkbp:publications |
conference proceedings
peer-reviewed journals |
| gptkbp:regulatoryCompliance |
gptkb:FDA
EMA |
| gptkbp:research_areas |
neurology
infectious diseases immunology |
| gptkbp:revenue |
$30 million (2020)
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
SGMO
|
| gptkbp:supplyChain |
ST-400
SB-525 TX200 |
| gptkbp:technology |
gptkb:Zinc_Finger_Nucleases
AAV vectors |
| gptkbp:website |
www.sangamo.com
|